FOR RESEARCH USE ONLY
PT-141

CHEMICAL PROPERTIES

CAS NUMBER189691-06-3
MOLECULAR WEIGHT1025.17 g/mol
MOLECULAR FORMULAC₅₀H₆₈N₁₄O₈

PHYSICAL PROPERTIES

APPEARANCEWhite lyophilized powder in sealed borosilicate glass vial.
SEQUENCEAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

PT-141

PT-141 (Bremelanotide) is a melanocortin receptor agonist and metabolite of Melanotan II. Studied for its central nervous system melanocortin pathway activity and FDA-approved for hypoactive sexual desire disorder.

1
Free shipping on orders over $150
2-day delivery
LOT NUMBERLMO-DS-0626-PT1-006
REPORT NO.RPT-20024
HPLC PURITY98.50%

7× Independently Tested

HPLC PurityIndependent lab
IdentitySequence confirmed
Net ContentExact mg verified
SterilityContamination-free
EndotoxinsLAL tested
Heavy MetalsICP-MS screened
Batch ConsistencyLot-to-lot stability
TESTED

RESEARCH USE ONLY

This compound is sold strictly for in vitro research and laboratory use. Not for human or animal consumption. Not a drug, food, or supplement. By purchasing you confirm you are a qualified researcher and will use this compound in compliance with all applicable laws. Must be 21 or older.

RESEARCH

Evaluation of the Safety, Pharmacokinetics and Pharmacodynamic Effects of Subcutaneously Administered PT-141
Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. · International Journal of Impotence Research · 2004
Phase I safety and pharmacokinetic study of subcutaneous PT-141 in healthy men and PDE5-inhibitor non-responders, establishing dose-response relationships for the melanocortin receptor agonist.
PMID 14999221
Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial
Clayton AH, Althof SE, Kingsberg S, et al. · Women's Health · 2016
Randomised placebo-controlled trial supporting the FDA approval of bremelanotide (Vyleesi) for hypoactive sexual desire disorder, demonstrating statistically significant improvement in sexual desire scores versus placebo.
An Effect on the Subjective Sexual Response in Premenopausal Women With Sexual Arousal Disorder by Bremelanotide (PT-141), a Melanocortin Receptor Agonist
Diamond LE, Earle DC, Heiman JR, et al. · Journal of Sexual Medicine · 2005
Phase II clinical trial demonstrating statistically significant improvements in subjective arousal parameters with PT-141 versus placebo in women with sexual arousal disorder, supporting its CNS-mediated mechanism independent of vascular pathways.
PMID 15735664

LAB RESULTS

LOT LMO-DS-0626-PT1-006 · CURRENT

Certificate of Analysis

PURITY
98.50%
CAS
189691-06-3
MW
1025.17 g/mol
APPEARANCE
White lyophilized powder in sealed borosilicate glass vial.
VERIFIED

Third-Party Report

TESTING LABIndependent Analytics LLC
TEST DATEJanuary 2025
METHODS USED
HPLCMSAAA
RESEARCH APPLICATIONS

What the literature covers.

  • MC3R/MC4R agonist studied for central melanocortin pathway activation
  • FDA-approved bremelanotide analogue with established clinical safety profile
  • Investigated for hypothalamic dopaminergic pathway modulation
  • Central nervous system melanocortin signalling studied independently of peripheral pathways

All compounds sold by Lumo are intended strictly for in vitro research and laboratory use only. These products are NOT intended for human consumption, medical, veterinary, or household use. By purchasing from Lumo, you acknowledge that you are a qualified researcher or institution and will use these products solely for research purposes in compliance with all applicable laws and regulations.

L-003

Stay current.

New lot releases, research updates, and product announcements.

Unsubscribe anytime. Research use communications only.

Research Use Only · Not for Human Consumption · For Laboratory Research Purposes Only

Your Cart

● All items for research use only. Not for human consumption.

Your cart is empty

Add compounds to get started